Phantom, essentially, your new opinion is that the vaccines of TPIV are of no value in determining share value. How unfortunate because what is of value is the therapeutic side of now MRKR. I disagree. Those that financed $70 million, and those who as institutions that bought in, did a thorough due dilligence on both companies having decided to combine.
Looking back the past several weeks, you seem to be softening your opinion of value. Is any of the above accurate? Are you establishing a new thought pattern on why the current depressed share price is what it is?
News 
Market Data 
Discover 
